Radiomics as a personalized medicine tool in lung cancer: Separating the hope from the hype

被引:77
|
作者
Fornacon-Wood, Isabella [1 ]
Faivre-Finn, Corinne [1 ,2 ]
O'Connor, James P. B. [1 ,3 ]
Price, Gareth J. [1 ]
机构
[1] Univ Manchester, Div Canc Sci, Wilmslow Rd, Manchester M20 4BX, Lancs, England
[2] Christie Hosp NHS Fdn Trust, Dept Radiat Oncol, Manchester, Lancs, England
[3] Christie Hosp NHS Fdn Trust, Dept Radiol, Manchester, Lancs, England
关键词
Radiomics; Imaging biomarkers; Lung cancer; Personalized medicine; INTEROBSERVER DELINEATION VARIABILITY; LYMPH-NODE METASTASIS; FEATURE STABILITY; PATHOLOGICAL RESPONSE; HISTOLOGIC SUBTYPE; RADIATION-THERAPY; CT IMAGES; STAGE I; FEATURES; PREDICTION;
D O I
10.1016/j.lungcan.2020.05.028
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Radiomics has become a popular image analysis method in the last few years. Its key hypothesis is that medical images harbor biological, prognostic and predictive information that is not revealed upon visual inspection. In contrast to previous work with a priori defined imaging biomarkers, radiomics instead calculates image features at scale and uses statistical methods to identify those most strongly associated to outcome. This builds on years of research into computer aided diagnosis and pattern recognition. While the potential of radiomics to aid personalized medicine is widely recognized, several technical limitations exist which hinder biomarker translation. Aspects of the radiomic workflow lack repeatability or reproducibility under particular circumstances, which is a key requirement for the translation of imaging biomarkers into clinical practice. One of the most commonly studied uses of radiomics is for personalized medicine applications in Non-Small Cell Lung Cancer (NSCLC). In this review, we summarize reported methodological limitations in CT based radiomic analyses together with suggested solutions. We then evaluate the current NSCLC radiomics literature to assess the risk associated with accepting the published conclusions with respect to these limitations. We review different complementary scoring systems and initiatives that can be used to critically appraise data from radiomics studies. Wider awareness should improve the quality of ongoing and future radiomics studies and advance their potential as clinically relevant biomarkers for personalized medicine in patients with NSCLC.
引用
收藏
页码:197 / 208
页数:12
相关论文
共 50 条
  • [1] Personalized medicine: hope or hype
    Wald, Nicholas J.
    Morris, Joan K.
    EUROPEAN HEART JOURNAL, 2012, 33 (13) : 1553 - 1554
  • [2] Personalized Medicine in Rheumatology - "hype or hope"?
    Burmester, G. -R.
    Feist, E.
    ZEITSCHRIFT FUR RHEUMATOLOGIE, 2013, 72 (01): : 10 - 11
  • [3] Commentary on "Personalized Medicine in Oncology: Hype or Hope?"
    Wang, Sue-Jane
    STATISTICS IN BIOPHARMACEUTICAL RESEARCH, 2009, 1 (04): : 457 - 461
  • [4] Separating antisense hope from hype
    Dev, S
    GENETIC ENGINEERING NEWS, 2004, 24 (18): : 59 - 60
  • [5] Personalisierte Medizin in der Rheumatologie – „hype or hope“?Personalized medicine in rheumatology – hype or hope?
    G.-R. Burmester
    E. Feist
    Zeitschrift für Rheumatologie, 2013, 72 (1) : 10 - 11
  • [6] Between hype and hope: What is really at stake with personalized medicine?
    Camille Abettan
    Medicine, Health Care and Philosophy, 2016, 19 : 423 - 430
  • [7] Personalized medicine: caught between hope, hype and the real world
    Dammann, Marc
    Weber, Frank
    CLINICS, 2012, 67 : 91 - 97
  • [8] Between hype and hope: What is really at stake with personalized medicine?
    Abettan, Camille
    MEDICINE HEALTH CARE AND PHILOSOPHY, 2016, 19 (03) : 423 - 430
  • [9] Sorafenib in Hepatocellular Carcinoma: Separating the Hype From the Hope
    Kelley, Robin K.
    Venook, Alan P.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (36) : 5845 - 5848
  • [10] Stem cell-based therapies for cancer treatment: separating hope from hype
    Stuckey, Daniel W.
    Shah, Khalid
    NATURE REVIEWS CANCER, 2014, 14 (10) : 683 - 691